Research desk · HALO · Nasdaq
HALO Stock
SEC financials, peer compare, and chart. Scores open the matching desk. Research only — not advice.
HALOZYME THERAPEUTICS, INC. · Biological Products, (No Diagnostic Substances)
HALOZYME THERAPEUTICS, INC. financial statements, chart, and peer compare from SEC filings.
HALOZYME THERAPEUTICS, INC. (HALO) develops biotechnology and life-science products.
- Market cap
- $12.39B
- P/E
- 19.93
- Op. margin
- 55.94%
- Profit margin
- 44.93%
- FCF margin
- 29.45%
- ROE
- 451.73%
Related Health Care stocks: EXEL stock financials · RPRX stock financials · PAHC stock financials · MRNA stock financials · ACAD stock financials
HALO financial statements
Each Compare name is its own block of years. Filing lines are SEC reports; P/E and price sit on that name’s TTM column only.
HALO stock peer compare
Each bar is that name’s percent vs its last TTM, on one zero line. Zero is unchanged. This ticker is the black bar.
Focus chart
Zero is unchanged vs last TTM. Every name is a percent for the metric you pick.
HALO stock peer headlines
Yahoo Finance RSS for HALO and the names in Compare.
| Ticker | Date | Headline |
|---|---|---|
| Loading headlines… | ||
HALO stock price chart
Overlays follow the Compare table.
HALO stock — research snapshot
Screen strengths and watchouts for HALO stock from the latest Misprise snapshot.
Strengths
- ROA 25.2% — strong returns on assets.
- ROE 451.7% — efficient equity returns.
- Operating margin 55.9% — solid operating leverage.
- Profit margin 44.9% — durable bottom-line quality.
- FCF margin 29.5% — cash conversion looks healthy.
Watchouts
- Debt/equity 16.38 — elevated leverage risk.
- Rev CAGR 5Y 39.2%
- Rev CAGR 3Y 28.4%
- EPS CAGR 5Y 22.4%
- EPS CAGR 3Y 21.3%
- FCF CAGR 5Y 64.9%
- FCF CAGR 3Y 39.9%
HALO stock FAQs
Short answers for HALO stock — statements, sector, and how this page is meant to be used.
What is HALO stock?
HALOZYME THERAPEUTICS, INC. (HALO) develops biotechnology and life-science products. HALO stock sits in Health Care (Biological Products, (No Diagnostic Substances)), listed on Nasdaq.
Where can I find HALOZYME THERAPEUTICS, INC. financial statements?
HALOZYME THERAPEUTICS, INC. financial statements — income statement, balance sheet, and cash flow — are on this HALO stock page, parsed from SEC 10-K and 10-Q filings. Use Annual or Quarterly, then the statement tabs. Research only.
What happened to HALO stock?
This page is a research snapshot of HALOZYME THERAPEUTICS, INC. (HALO) from the latest SEC filings in the Misprise database as of TTM. It is not a news feed or a delisting notice. Open the financial statements, chart, and peer compare below, then read the filings. Research only — not financial advice.
Does this page show the HALO stock price?
The live chart on this HALO stock page is the same TradingView chart as the screener. Statement tables use SEC filings. Any price or multiple on the TTM column is a market snapshot from the last seed, not a real-time quote. Research only.
What sector is HALO stock in?
HALOZYME THERAPEUTICS, INC. is classified in Biological Products, (No Diagnostic Substances), inside the Health Care sector, and trades on Nasdaq. This page is a research snapshot, not a full company profile.
How do I read HALO financial statements?
Start with this ticker’s block (TTM, then its fiscal years or quarters). Each Compare name is a separate block of its own periods — not mixed by year. A blank is a period we do not have, not a zero. Research only — not a buy or sell.
Where does the HALO statement data come from?
Income, balance sheet, and cash-flow lines are parsed from SEC company filings (10-K / 10-Q and 20-F). TTM is the last four reported quarters added together, not a separate filing. P/E, forward P/E, price, and market cap are a market quote at last seed — trailing P/E from the quote when available, otherwise last price divided by TTM EPS. They are not 10-K line items and appear on the TTM column only. Research only — not financial advice.
Where can I find the HALO income statement, balance sheet, and cash flow?
On this HALO stock page, open Financial statements and use the Income, Balance sheet, and Cash flow tabs. Growth and valuation sit under More. Filing figures are from SEC reports; valuation multiples are the market snapshot described above.
What is the Misprise Score for HALO stock?
HALO stock currently scores 62/100 (Constructive (60–72)). HALOZYME THERAPEUTICS, INC. is constructive on the screen — worth a deeper look at compounding and filings before treating it as high conviction. The score is a screen of quality, growth, and balance-sheet inputs — not a price target. Compare it in the Misprise screener; it is not a separate score page.
How is the HALO comparison winner decided?
Lead and Tie follow the number printed on each factor row, not a blended category score. Growth, quality, score, current ratio, and coverage: the higher figure leads. Value multiples (P/E, PEG, P/B, P/S) and debt ratios: the lower figure leads. Tie appears only when those printed numbers match. The header winner is whoever takes more of those five rows. CAGR uses the 5-year horizon and drops to 3-year only when both names report it. Research only — not a buy or sell.
What is the Anomaly Score on this HALO page?
Anomaly Score is how unusual a filing pattern is versus this company’s own history and its industry — not the same as Misprise Score. A high anomaly with a weak Misprise Score is often a noisy name. Open the anomaly detector to see the flag. Research only — not financial advice.
What does the green grant dot mean on HALO stock?
A green circle next to the title means this ticker appears in the Misprise grants calendar with a recent federal award (USASpending / SAM). Tap the dot for date, agency, and amount when available. It is a research flag only — not a buy or sell signal.
Is HALO stock a buy?
No recommendation either way. This HALO stock page organizes statements, ratios, and peers so you can do your own work. It is educational only — not advice to buy or sell HALOZYME THERAPEUTICS, INC..